Earnings | Ajanta Pharma Ltd. (NSE: AJANTAPHARMA): Q4FY23 Results Out; Total Income rises 2.1% YoY.

Ajanta Pharma is a leading Indian pharmaceutical company that specializes in the development, manufacturing, and marketing of high-quality specialty pharmaceutical finished dosages. Founded in 1973, the company has a strong focus on research and development and has invested heavily in building state-of-the-art facilities and advanced technologies. Ajanta Pharma has a diverse product portfolio that includes medicines for various therapeutic categories such as cardiovascular, dermatology, ophthalmology, and pain management, among others. The company has a global presence and exports its products to over 50 countries worldwide.

• Ajanta Pharma Ltd. reported Total Income for Q4 FY23 of ₹919 Crore up from ₹900 Crore year on year, a growth of 2.1%.
• Total Expenses for Q4 FY23 of ₹767 Crore up from ₹702 Crore year on year, a growth of 9%.
• Consolidated Net Profit of ₹122 Crore, down 20% from ₹151 Crore in the same quarter of the previous year. 
• The Earnings per Share is ₹9.54, down 18% from ₹11.66 in the same quarter of the previous year.